IVERIC bio Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 163

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5.9B

IVERIC bio General Information

Description

Developer of biopharmaceutical products designed for the treatment of retinal diseases. The company offers therapeutic candidates and gene therapies for age-related macular degeneration and orphan inherited retinal diseases, providing intravitreal services that inhibit complement factors to reduce disease progression and prevent vision loss in patients with unmet medical needs.

Contact Information

Formerly Known As
Ophthotech
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 8 Sylvan Way
  • Parsippany, NJ 07054
  • United States
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 8 Sylvan Way
  • Parsippany, NJ 07054
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IVERIC bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Merger/Acquisition 11-Jul-2023 $5.9B Completed Generating Revenue/Not Profitable
16. 2PO 05-Dec-2022 Completed Generating Revenue/Not Profitable
15. PIPE 22-Jun-2020 Completed Generating Revenue/Not Profitable
14. PIPE 01-Jan-2020 Completed Generating Revenue/Not Profitable
13. PIPE 30-Oct-2018 Completed Generating Revenue/Not Profitable
12. Secondary Transaction - Open Market 17-Apr-2017 Completed Generating Revenue/Not Profitable
11. Secondary Transaction - Open Market 15-Apr-2016 Completed Generating Revenue/Not Profitable
10. PIPE 24-Aug-2015 Completed Generating Revenue/Not Profitable
9. Secondary Transaction - Open Market 15-Apr-2015 $389M Completed Generating Revenue/Not Profitable
8. PIPE 16-Sep-2014 $50M $389M Completed Generating Revenue/Not Profitable
To view IVERIC bio’s complete valuation and funding history, request access »

IVERIC bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical products designed for the treatment of retinal diseases. The company offers therapeutic c
Pharmaceuticals
Parsippany, NJ
163 As of 2022

San Diego, CA
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IVERIC bio Competitors (79)

One of IVERIC bio’s 79 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avidity Biosciences Formerly VC-backed San Diego, CA
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Genentech Formerly VC-backed South San Francisco, CA
Adverum Biotechnologies Formerly VC-backed Redwood City, CA
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
You’re viewing 5 of 79 competitors. Get the full list »

IVERIC bio Patents

IVERIC bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024137916-A1 Pharmaceutical compositions for delivery to the eye Inactive 23-Dec-2022
WO-2024006902-A2 Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same Inactive 30-Jun-2022
WO-2024006902-A3 Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same Inactive 30-Jun-2022
WO-2024006902-A9 Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same Inactive 30-Jun-2022
CA-3197023-A1 Methods for treating ophthalmological conditions Pending 01-Nov-2020 C12N15/115
To view IVERIC bio’s complete patent history, request access »

IVERIC bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IVERIC bio Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avoro Capital Venture Capital Minority
Blackstone Life Sciences Other Private Equity Minority
Foresite Capital Growth/Expansion Minority
Frazier Healthcare Partners PE/Buyout Minority
HBM Healthcare Investments Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

IVERIC bio Acquisitions (1)

IVERIC bio’s most recent deal was a Merger/Acquisition with Inception 4 for . The deal was made on 31-Oct-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Inception 4 31-Oct-2018 Merger/Acquisition Biotechnology
To view IVERIC bio’s complete acquisitions history, request access »

IVERIC bio ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

20.65 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view IVERIC bio’s complete esg history, request access »

IVERIC bio FAQs

  • When was IVERIC bio founded?

    IVERIC bio was founded in 2007.

  • Where is IVERIC bio headquartered?

    IVERIC bio is headquartered in Parsippany, NJ.

  • What is the size of IVERIC bio?

    IVERIC bio has 163 total employees.

  • What industry is IVERIC bio in?

    IVERIC bio’s primary industry is Pharmaceuticals.

  • Is IVERIC bio a private or public company?

    IVERIC bio is a Private company.

  • What is the current valuation of IVERIC bio?

    The current valuation of IVERIC bio is .

  • What is IVERIC bio’s current revenue?

    The current revenue for IVERIC bio is .

  • How much funding has IVERIC bio raised over time?

    IVERIC bio has raised $863M.

  • Who are IVERIC bio’s investors?

    Avoro Capital, Blackstone Life Sciences, Foresite Capital, Frazier Healthcare Partners, and HBM Healthcare Investments are 5 of 11 investors who have invested in IVERIC bio.

  • Who are IVERIC bio’s competitors?

    Avidity Biosciences, Foventa Therapeutics, Genentech, Adverum Biotechnologies, and ONL Therapeutics are some of the 79 competitors of IVERIC bio.

  • When was IVERIC bio acquired?

    IVERIC bio was acquired on 11-Jul-2023.

  • Who acquired IVERIC bio?

    IVERIC bio was acquired by Astellas Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process